Hyperoxaluria - Pipeline Review, H1 2016

  • ID: 3758993
  • Drug Pipelines
  • 53 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Digna Biotech, S.L.
  • OxThera AB
  • MORE
Hyperoxaluria - Pipeline Review, H1 2016

Summary

‘Hyperoxaluria - Pipeline Review, H1 2016’, provides an overview of the Hyperoxaluria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperoxaluria
- The report reviews pipeline therapeutics for Hyperoxaluria by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hyperoxaluria therapeutics and enlists all their major and minor projects
- The report assesses Hyperoxaluria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hyperoxaluria

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hyperoxaluria
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hyperoxaluria pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Digna Biotech, S.L.
  • OxThera AB
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Hyperoxaluria Overview

Therapeutics Development

Pipeline Products for Hyperoxaluria - Overview

Hyperoxaluria - Therapeutics under Development by Companies

Hyperoxaluria - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Hyperoxaluria - Products under Development by Companies

Hyperoxaluria - Companies Involved in Therapeutics Development

Allena Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc.

Digna Biotech, S.L.

OxThera AB

Hyperoxaluria - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ALLN-177 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ALLN-230 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ALN-GO1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DB-027 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DCR-PH - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DCRPH-1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Oxabact - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Hyperoxaluria - Recent Pipeline Updates

Hyperoxaluria - Dormant Projects

Hyperoxaluria - Discontinued Products

Hyperoxaluria - Product Development Milestones

Featured News & Press Releases

May 13, 2016: Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1

May 05, 2016: FDA Grants Orphan Drug Designation to Allena’s Investigational Therapy for the Treatment of Pediatric Hyperoxaluria

Feb 10, 2016: Allena Pharmaceuticals Initiates Patient Treatment in Third Phase 2 Trial of ALLN-177 for Secondary Hyperoxaluria

Dec 21, 2015: Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1 in Healthy Volunteers

Nov 12, 2015: Allena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ALLN-177 Program at American Society of Nephrology Kidney Week

Nov 04, 2015: Allena Pharmaceuticals to Present Phase 2 Data on ALLN-177 Program at ASN Kidney Week 2015

Sep 02, 2015: Dicerna Pharmaceuticals Submits Investigational New Drug Application for DCR-PH1, an Investigational Therapy for Primary Hyperoxaluria Type 1 (PH1)

Aug 06, 2015: EMA Grants Orphan Drug Designation to DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1

Aug 04, 2015: Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria

Apr 23, 2015: FDA Grants Orphan Drug Designation for DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hyperoxaluria, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Hyperoxaluria - Pipeline by Allena Pharmaceuticals, Inc., H1 2016

Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016

Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016

Hyperoxaluria - Pipeline by Digna Biotech, S.L., H1 2016

Hyperoxaluria - Pipeline by OxThera AB, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Hyperoxaluria Therapeutics - Recent Pipeline Updates, H1 2016

Hyperoxaluria - Dormant Projects, H1 2016

Hyperoxaluria - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Hyperoxaluria, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Allena Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
OxThera AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll